Evidence map›Paper›PMID 40750774›Full record

Trial reportBlood cancer journal2025

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Won-Seog Kim and 17 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01777152 (A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01777152 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

TypeinterventionalSponsorSeagen Inc.Ran2013 to 2020Enrolled452ConditionsAnaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell LymphomaArmsbrentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Eva Domingo-DomènechDepartment of Hematology, Institut Catala D'Oncologia, Hospital Duran i Reynals; Institut de reserca IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. edomingo@iconcologia.net.ORCID 0000-0001-8907-090X
Barbara ProDivision of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Tim IllidgeNIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, University of Manchester, Manchester, UK.
Steven HorwitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6399-2006
Lorenz TrumperUniversitätsmedizin Göttingen, Göttingen, Germany.ORCID 0000-0002-9798-4573
Swami IyerMD Anderson Cancer Center/University of Texas, Houston, TX, USA.
Ranjana AdvaniDivision of Oncology, Department of Medicine Division of Oncology, Stanford University, Stanford, CA, USA.
Nancy L BartlettSiteman Cancer Center, Washington University School of Medicine in St Louis, St. Louis, MO, USA.
Jacob Haaber ChristensenOdense University Hospital, Odense, Denmark.
Won-Seog KimDivision of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Tatyana FeldmanJohn Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA.
Ilseung ChoiDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Giuseppe GrittiDivision of Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Bergamo, Italy.ORCID 0000-0002-6789-5123
David Belada4th Department of Internal Medicine -Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czechia.
Andrei ShustovUniversity of Washington Seattle Cancer Care Alliance & Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Arpad IllesDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Pier Luigi ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.ORCID 0000-0002-2112-2651
Andreas HüttmannUniversitatsklinikum Essen, Nordrhein-Westfalen, Germany.ORCID 0000-0003-2230-3873
Marek TrnenyFirst Faculty of Medicine at Charles University Hospital, Prague, Czechia.ORCID 0000-0002-6952-6073
Steven Le GouillService d'hématologie, Institut Curie, Saint Cloud, France, Versailles, France.
Deepa JagadeeshDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jonathan W FriedbergWilmot Cancer Institute, University of Rochester, Rochester, NY, USA.
Meredith LittleTakeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA.
Cassie DongTakeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA.
Michelle FanaleSeagen Inc, Bothell, WA, USA.
Keenan FentonSeagen Inc, Bothell, WA, USA.
Kerry J SavageCentre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registrationClinicalTrials.gov number: NCT01777152.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinLymphoma, Large-Cell, AnaplasticAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedTreatment OutcomeBrentuximab Vedotin

Identifiers

PMID40750774
PMCPMC12317119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.